228 related articles for article (PubMed ID: 16802853)
1. Equivalent pharmacokinetics of the active metabolite of ciclesonide with and without use of the AeroChamber Plus spacer for inhalation.
Drollmann A; Nave R; Steinijans VW; Baumgärtner E; Bethke TD
Clin Pharmacokinet; 2006; 45(7):729-36. PubMed ID: 16802853
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic disposition of inhaled ciclesonide and its metabolite desisobutyryl-ciclesonide in healthy subjects and patients with asthma are similar.
Nave R; Gunawardena KA; Zech K; Bethke TD
Int J Clin Pharmacol Ther; 2006 Jan; 44(1):1-7. PubMed ID: 16425964
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of ciclesonide and desisobutyryl ciclesonide after administration via aqueous nasal spray or hydrofluoroalkane nasal aerosol compared with orally inhaled ciclesonide: an open-label, single-dose, three-period crossover study in healthy volunteers.
Nave R; Herzog R; Laurent A; Wingertzahn MA
Clin Ther; 2009 Dec; 31(12):2988-99. PubMed ID: 20110036
[TBL] [Abstract][Full Text] [Related]
4. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma.
Newman S; Salmon A; Nave R; Drollmann A
Respir Med; 2006 Mar; 100(3):375-84. PubMed ID: 16275052
[TBL] [Abstract][Full Text] [Related]
5. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects.
Nave R; Zech K; Bethke TD
Eur J Clin Pharmacol; 2005 May; 61(3):203-8. PubMed ID: 15824911
[TBL] [Abstract][Full Text] [Related]
6. Repeated-dose pharmacokinetics of inhaled ciclesonide (CIC-HFA) in Japanese children with bronchial asthma: a phase I study.
Teramoto T; Matsui E; Fukao T; Sakai K; Yonezawa H; Kato Z; Ohnishi H; Kaneko H; Kondo N; Azuma J; Nishima S
Allergol Int; 2012 Dec; 61(4):619-24. PubMed ID: 23000724
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma.
Richter K; Kanniess F; Biberger C; Nave R; Magnussen H
J Clin Pharmacol; 2005 Feb; 45(2):146-52. PubMed ID: 15647406
[TBL] [Abstract][Full Text] [Related]
8. Determination of lung deposition following inhalation of ciclesonide using different bioanalytical procedures.
Nave R
Bioanalysis; 2010 Apr; 2(4):807-14. PubMed ID: 21083275
[TBL] [Abstract][Full Text] [Related]
9. Deposition and metabolism of inhaled ciclesonide in the human lung.
Nave R; Watz H; Hoffmann H; Boss H; Magnussen H
Eur Respir J; 2010 Nov; 36(5):1113-9. PubMed ID: 20351025
[TBL] [Abstract][Full Text] [Related]
10. Similar Results in Children with Asthma for Steady State Pharmacokinetic Parameters of Ciclesonide Inhaled with or without Spacer.
Boss H; Minic P; Nave R
Clin Med Insights Pediatr; 2010; 4():1-10. PubMed ID: 23761990
[TBL] [Abstract][Full Text] [Related]
11. Lack of pharmacokinetic drug-drug interaction between ciclesonide and erythromycin.
Nave R; Drollmann A; Steinijans VW; Zech K; Bethke TD
Int J Clin Pharmacol Ther; 2005 Jun; 43(6):264-70. PubMed ID: 15968883
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma.
Xu J; Nave R; Lahu G; Derom E; Derendorf H
J Clin Pharmacol; 2010 Oct; 50(10):1118-27. PubMed ID: 20150524
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects.
Nave R; Bethke TD; van Marle SP; Zech K
Clin Pharmacokinet; 2004; 43(7):479-86. PubMed ID: 15139796
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma.
Boulet LP; Drollmann A; Magyar P; Timar M; Knight A; Engelstätter R; Fabbri L
Respir Med; 2006 May; 100(5):785-94. PubMed ID: 16427266
[TBL] [Abstract][Full Text] [Related]
15. Ciclesonide--a novel corticosteroid for the management of asthma.
Chopra D; Bhandari B; Wardhan N
Curr Clin Pharmacol; 2012 May; 7(2):73-7. PubMed ID: 22283615
[TBL] [Abstract][Full Text] [Related]
16. Ciclesonide disposition and metabolism: pharmacokinetics, metabolism, and excretion in the mouse, rat, rabbit, and dog.
Guo Z; Gu Z; Howell SR; Chen K; Rohatagi S; Cai L; Wu J; Stuhler J
Am J Ther; 2006; 13(6):490-501. PubMed ID: 17122529
[TBL] [Abstract][Full Text] [Related]
17. An investigation of the pharmacokinetics, pharmacodynamics, safety, and tolerability of ciclesonide hydrofluoroalkane nasal aerosol in healthy subjects and subjects with perennial allergic rhinitis.
Ratner P; Wingertzahn MA; Herzog R; Huang H; Desai SY; Maier G; Nave R
Pulm Pharmacol Ther; 2011 Aug; 24(4):426-33. PubMed ID: 21501692
[TBL] [Abstract][Full Text] [Related]
18. Effect of coadministered ketoconazole, a strong cytochrome P450 3A4 enzyme inhibitor, on the pharmacokinetics of ciclesonide and its active metabolite desisobutyryl-ciclesonide.
Böhmer GM; Drollmann A; Gleiter CH; Nave R
Clin Pharmacokinet; 2008; 47(5):343-9. PubMed ID: 18399715
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetic and pharmacodynamic profile of inhaled ciclesonide.
Nave R
Clin Pharmacokinet; 2009; 48(4):243-52. PubMed ID: 19492869
[TBL] [Abstract][Full Text] [Related]
20. Two-dimensional and three-dimensional imaging show ciclesonide has high lung deposition and peripheral distribution: a nonrandomized study in healthy volunteers.
Leach CL; Bethke TD; Boudreau RJ; Hasselquist BE; Drollmann A; Davidson P; Wurst W
J Aerosol Med; 2006; 19(2):117-26. PubMed ID: 16796536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
